» Articles » PMID: 16818738

Regulation of Trafficking Receptor Expression in Human Forkhead Box P3+ Regulatory T Cells

Overview
Journal J Immunol
Date 2006 Jul 5
PMID 16818738
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

Forkhead Box P3(+) (FOXP3(+)) T cells are regulatory cells important for maintaining immune tolerance. While chemokine- and other homing-receptors are important for T cell migration, it has been unclear how they are regulated in FOXP3(+) T cells. We thoroughly investigated, ex vivo and in vitro, the regulation of chemokine receptor expression on human FOXP3(+) T cells in neonatal cord blood, adult peripheral blood, and tonsils. We found that human FOXP3(+) T cells undergo changes in trafficking receptors according to their stages of activation and differentiation. FOXP3(+) T cells are divided into CD45RA(+) (naive type) and CD45RO(+) (memory type) FOXP3(+) T cells in neonatal blood, adult blood, and tonsils. CD45RA(+)FOXP3(+) T cells mainly express lymphoid tissue homing receptors (CD62L, CCR7, and CXCR4), while CD45RO(+)FOXP3(+) T cells highly express both Th1 and Th2-associated trafficking receptors along with the lymphoid tissue homing receptors at reduced frequencies. Up-regulation of Th1/Th2-associated trafficking receptors begins with activation of CD45RA(+)FOXP3(+) T cells and is completed after their differentiation to CD45RO(+) cells. Some chemokine receptors such as CXCR5 and CXCR6 are preferentially expressed by many FOXP3(+) cells at a specific stage (CD69(+)CD45RO(+)) in tonsils. Our in vitro differentiation study demonstrated that CD45RA(+)FOXP3(+) T cells indeed undergo chemokine receptor switch from CD45RA(+) (secondary lymphoid tissue homing) to CD45RO(+) type (lymphoid and nonlymphoid tissue homing). The orderly regulation of trafficking receptors in FOXP3(+) T cells according to stages of differentiation and activation is potentially important for their tissue-specific migration and regulation of immune responses in humans.

Citing Articles

Beyond FOXP3: a 20-year journey unravelling human regulatory T-cell heterogeneity.

Santosh Nirmala S, Kayani K, Gliwinski M, Hu Y, Iwaszkiewicz-Grzes D, Piotrowska-Mieczkowska M Front Immunol. 2024; 14:1321228.

PMID: 38283365 PMC: 10811018. DOI: 10.3389/fimmu.2023.1321228.


Promises and Pitfalls of Next-Generation Treg Adoptive Immunotherapy.

Christofi P, Pantazi C, Psatha N, Sakellari I, Yannaki E, Papadopoulou A Cancers (Basel). 2023; 15(24).

PMID: 38136421 PMC: 10742252. DOI: 10.3390/cancers15245877.


Identification and classification of distinct surface markers of T regulatory cells.

Wegrzyn A, Kedzierska A, Obojski A Front Immunol. 2023; 13:1055805.

PMID: 36741366 PMC: 9892051. DOI: 10.3389/fimmu.2022.1055805.


The frequency of Treg subsets distinguishes disease activity in ANCA vasculitis.

Agosto-Burgos C, Wu E, Iannone M, Hu Y, Hogan S, Henderson C Clin Transl Immunology. 2022; 11(11):e1428.

PMID: 36381498 PMC: 9652144. DOI: 10.1002/cti2.1428.


Anti-neoplastic sulfonamides alter the metabolic homeostasis and disrupt the suppressor activity of regulatory T cells.

Gedaly R, Cornea V, Turcios L, Edmisson J, Harris D, Watt D Sci Rep. 2022; 12(1):19112.

PMID: 36352020 PMC: 9646802. DOI: 10.1038/s41598-022-23601-2.